Please ensure Javascript is enabled for purposes of website accessibility
UK Coronavirus Vaccine Prompts Immune Response in Early Test
gvw_ap_news
By Associated Press
Published 4 years ago on
July 20, 2020

Share

LONDON — Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot.

In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55 that lasted at least two months after they were immunized.
British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. Such early trials are designed to evaluate safety and see what kind of immune response was provoked, but can’t tell if the vaccine truly protects.
In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55 that lasted at least two months after they were immunized.
“We are seeing good immune response in almost everybody,” said Dr. Adrian Hill, director of the Jenner Institute at Oxford University. “What this vaccine does particularly well is trigger both arms of the immune system,” he said.
Hill said that neutralizing antibodies are produced — molecules which are key to blocking infection. In addition, the vaccine also causes a reaction in the body’s T-cells which help to fight off the coronavirus.
The experimental COVID-19 vaccine caused minor side effects like fever, chills and muscle pain more often than in those who got a control meningitis vaccine.
Hill said that larger trials evaluating the vaccine’s effectiveness, involving about 10,000 people in the U.K. as well as participants in South Africa and Brazil are still underway. Another big trial is slated to start in the U.S. soon, aiming to enroll about 30,000 people.
How quickly scientists are able to determine the vaccine’s effectiveness will depend largely on how much more transmission there is, but Hill estimated they might have sufficient data by the end of the year to decide if the vaccine should be adopted for mass vaccination campaigns.

Hill Said Oxford Has Partnered With Drugmaker AstraZeneca to Produce Their Vaccine Globally

He said the vaccine seemed to produce a comparable level of antibodies to those produced by people who recovered from a COVID-19 infection and hoped that the T-cell response would provide extra protection.
“There’s increasing evidence that having a T-cell response as well as antibodies could be very important in controlling COVID-19,” Hill said. He suggested the immune response might be boosted after a second dose; their trial tested two doses administered about four weeks apart.
Hill said Oxford’s vaccine is designed to reduce disease and transmission. It uses a harmless virus — a chimpanzee cold virus, engineered so it can’t spread — to carry the coronavirus’ spike protein into the body, which should trigger an immune system response.
Hill said Oxford has partnered with drugmaker AstraZeneca to produce their vaccine globally, and that the company has already committed to making 2 billion doses.
“Even 2 billion doses may not be enough,” he said, underlining the importance of having multiple shots to combat the coronavirus.
“There was a hope that if we had a vaccine quickly enough, we could put out the pandemic,” Hill said, noting the continuing surge of infections globally. “I think its going to be very difficult to control this pandemic without a vaccine.”
Numerous countries including Germany, France, the Netherlands, Italy, U.S. and the U.K. have all signed deals to receive hundreds of millions of doses of the vaccine — which has not yet been licensed — with the first deliveries scheduled for the fall. British politicians have promised that if the shot proves effective, Britons will be the first to get it.
Chinese researchers also published a study on their experimental COVID-19 vaccine in the Lancet on Monday, using a similar technique as the Oxford scientists. They reported that in their study of about 500 people, an immune response was detected in those who were immunized. But they noted that because the participants weren’t exposed to the coronavirus afterwards, it wasn’t possible to tell if they were protected from the disease.

Nearly Two Dozen Potential Vaccines Are in Various Stages of Human Testing Worldwide

CanSino Biologics’ vaccine is made similarly to Oxford’s except the Chinese shot is made with a human cold virus, and the study showed people whose bodies recognized it didn’t get as much of the presumed COVID-19 benefit. Still, China’s government already gave special approval for the military to use CanSino’s vaccine while it explores final-stage studies.

British officials said Monday they had also signed a deal to buy 90 million doses of experimental COVID-19 vaccines being developed by the pharmaceutical giant Pfizer and others.
In an accompanying editorial, Naor Bar-Zeev and William Moss of the Johns Hopkins Bloomberg School of Public Health called both the Oxford and Chinese results “encouraging” but said further judgment should wait until the vaccine is tested on much bigger populations.
Bar-Zeev and Moss also called for any effective COVID-19 vaccine to be distributed equitably around the world.
“Global planning is underway, but should be underpinned and informed by specific local realities,” they wrote. “Only this way can these very encouraging first earlyphase randomised trial results yield the global remedy for which we all yearn.”
Last week, American researchers announced that the first COVID-19 vaccine tested there boosted people’s immune systems just as scientists had hoped and the shots will now enter the final phase of testing. That vaccine, developed by the National Institutes of Health and Moderna, produced the molecules key to blocking infection in volunteers who got it, at levels comparable to people who survived a COVID-19 infection.
Nearly two dozen potential vaccines are in various stages of human testing worldwide, with a handful entering necessary late-stage testing to prove effectiveness.
British officials said Monday they had also signed a deal to buy 90 million doses of experimental COVID-19 vaccines being developed by the pharmaceutical giant Pfizer and others.
In a statement, the British government said it had secured access to a vaccine candidate being developed by Pfizer and BioNTech, in addition to another experimental vaccine researched by Valneva.

DON'T MISS

What to Know About Pam Bondi, Trump’s New Pick for Attorney General

DON'T MISS

North Korean Leader Says Past Diplomacy Only Confirmed US Hostility

DON'T MISS

Democrats Strike Deal to Get More Biden Judges Confirmed Before Congress Adjourns

DON'T MISS

Newsom Gaslights on Potential Gas Price Hikes in Fresno Visit

DON'T MISS

Automakers to Trump: Please Require Us to Sell Electric Vehicles

DON'T MISS

President Biden Welcomes 2024 NBA Champion Boston Celtics to White House

DON'T MISS

Ohtani Makes History With 3rd MVP, Judge Claims 2nd AL Honor

DON'T MISS

Trump Chooses Pam Bondi for Attorney General Pick After Gaetz Withdraws

DON'T MISS

Average Rate on a 30-Year Mortgage in the US Rises to Highest Level Since July

DON'T MISS

Cutting in Line? American Airlines’ New Boarding Tech Might Stop You at Now Over 100 Airports

UP NEXT

Putin Says Russia Has Tested a New Intermediate Range Missile in a Strike on Ukraine

UP NEXT

What Will Happen to CNBC and MSNBC When They No Longer Have a Corporate Connection to NBC News?

UP NEXT

Pope to Make Late Italian Teenager Carlo Acutis the First Millennial Saint on April 27

UP NEXT

US Vetoes UN Ceasefire Resolution in Gaza Conflict

UP NEXT

Israeli Officials Demand the Right to Strike Hezbollah Under Any Cease-Fire Deal for Lebanon

UP NEXT

Spain Will Legalize Hundreds of Thousands of Undocumented Migrants in the Next 3 Years

UP NEXT

TSMC Walks a Geopolitical Tightrope

UP NEXT

Volunteers Came Back to Nonprofits in 2023, After the Pandemic Tanked Participation

UP NEXT

New Study: Proposed Trump Tariffs Could Cost US Consumers $78 Billion a Year

UP NEXT

Iran Defies International Pressure, Increasing Its Stockpile of Near Weapons-Grade Uranium, UN Says

Newsom Gaslights on Potential Gas Price Hikes in Fresno Visit

10 hours ago

Automakers to Trump: Please Require Us to Sell Electric Vehicles

10 hours ago

President Biden Welcomes 2024 NBA Champion Boston Celtics to White House

10 hours ago

Ohtani Makes History With 3rd MVP, Judge Claims 2nd AL Honor

11 hours ago

Trump Chooses Pam Bondi for Attorney General Pick After Gaetz Withdraws

11 hours ago

Average Rate on a 30-Year Mortgage in the US Rises to Highest Level Since July

11 hours ago

Cutting in Line? American Airlines’ New Boarding Tech Might Stop You at Now Over 100 Airports

12 hours ago

MLB Will Test Robot Umpires at 13 Spring Training Ballparks Hosting 19 Teams

12 hours ago

Death Toll in Gaza From Israel-Hamas War Passes 44,000, Palestinian Officials Say

12 hours ago

Jussie Smollett’s Conviction in 2019 Attack on Himself Is Overturned

12 hours ago

What to Know About Pam Bondi, Trump’s New Pick for Attorney General

NEW YORK — Pam Bondi, the former Florida attorney general, was chosen Thursday by Donald Trump to serve as U.S. attorney general hours after...

8 hours ago

8 hours ago

What to Know About Pam Bondi, Trump’s New Pick for Attorney General

9 hours ago

North Korean Leader Says Past Diplomacy Only Confirmed US Hostility

9 hours ago

Democrats Strike Deal to Get More Biden Judges Confirmed Before Congress Adjourns

10 hours ago

Newsom Gaslights on Potential Gas Price Hikes in Fresno Visit

President Joe Biden with Mary Barra, the chief executive of General Motors, at the Detroit Auto Show, Sept. 14, 2022. President-elect Donald Trump has promised to erase the Biden administration’s tailpipe rules designed to get carmakers to produce electric vehicles, but most U.S. automakers want to keep them. (Doug Mills/The New York Times)
10 hours ago

Automakers to Trump: Please Require Us to Sell Electric Vehicles

10 hours ago

President Biden Welcomes 2024 NBA Champion Boston Celtics to White House

11 hours ago

Ohtani Makes History With 3rd MVP, Judge Claims 2nd AL Honor

Former Florida Attorney General Pam Bondi, speaks before Republican presidential nominee former President Donald Trump arrives to speak at a campaign rally at First Horizon Coliseum, Saturday, Nov. 2, 2024, in Greensboro, NC. (AP/Alex Brandon)
11 hours ago

Trump Chooses Pam Bondi for Attorney General Pick After Gaetz Withdraws

Help continue the work that gets you the news that matters most.

Search

Send this to a friend